Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-002040
Filing Date
2022-08-04
Accepted
2022-08-04 16:06:41
Documents
48
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20220630x10q.htm   iXBRL 10-Q 709176
2 EX-31.1 enzn-20220630xex31d1.htm EX-31.1 12983
3 EX-32.1 enzn-20220630xex32d1.htm EX-32.1 6786
  Complete submission text file 0001410578-22-002040.txt   2906091

Data Files

Seq Description Document Type Size
4 EX-101.SCH enzn-20220630.xsd EX-101.SCH 30598
5 EX-101.CAL enzn-20220630_cal.xml EX-101.CAL 15630
6 EX-101.DEF enzn-20220630_def.xml EX-101.DEF 94982
7 EX-101.LAB enzn-20220630_lab.xml EX-101.LAB 214799
8 EX-101.PRE enzn-20220630_pre.xml EX-101.PRE 165466
42 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20220630x10q_htm.xml XML 312034
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 221136511
SIC: 2836 Biological Products, (No Diagnostic Substances)